| Pathologically-induced tolerogenic DC |
Pathogen-induced tolerogenic DC
|
| F. hepatica products |
CD4+CD25+Foxp3+ |
BMDC |
i-DC |
|
|
Falcón et al., 2010 (320) |
|
| S. japonicum SJMHE1 peptide |
CD4+CD25+* |
BMDC |
i-DC |
|
DTH |
Wang et al., 2009 (321) |
|
| C. albicans |
CD4+Foxp3+IL-10+ |
BMDC |
|
|
IBD |
Bonifazi et al., 2009 (322) |
|
| Monophosphoryl Lipid A |
CD4+Foxp3+IL-10+TGFβ+ |
Oral cavity |
Oral-m-LC |
|
|
Allam et al., 2008 (323) |
|
| LPS |
CD4+CD25+Foxp3+ |
BMDC |
|
|
EAU |
Lau et al., 2008 (324) |
|
|
Cryptococcus neoformans Glucuronoxylomannan |
CD4+Foxp3+ |
BMDC |
|
|
|
Liu et al., 2008 (325) |
|
| Curcuma longa L. products (Curcumin) |
CD4+CD25+Foxp3+IL10+* |
BMDC |
|
|
IBD |
Cong et al., 2009 (208) |
|
|
Yersinia virulence factor |
CD4+IL-10+ |
BMDC |
|
|
|
Depaolo et al., 2008 (326) |
|
Tumor-induced tolerogenic DC
|
| Pancreatic tumor-derived Mucins |
* |
huMoDC |
|
|
|
Monti et al., 2004 (327) |
|
| B16 Melanoma |
CD4+CD25+Foxp3+* |
Spleen |
iDC |
TGFβ |
TI |
Ghiringhelli et al., 2005 (328) |
|
| P815 Mastocytoma |
CD4+IL-10+ |
Tumor-infiltrating |
CD4−CD8− |
|
TI |
Liu et al., 2005 (154) |
|
| MO4 Carcinoma |
CD4+IL-10+* |
Spleen |
CD4−CD8− |
|
TI |
Zhang et al., 2005 (155) |
|
| Necrotic myeloma cells |
CD4+IL-10+ |
huMoDC |
|
|
|
Fiore et al., 2005 (156) |
|
| Ovarian carcinoma |
CD8+CCR7+CD45RO+IL-10+* |
Ovary ascite |
pDC |
|
CP |
Wei et al., 2005 (157) |
|
| Lung carcinoma cells |
CD4+CD25+Foxp3+* |
huMoDC |
iDC |
|
|
Dumitriu et al., 2009 (158) |
|
Retrocontrol-induced tolerogenic DC
|
| CD8+CD28− suppressor |
CD4+ |
huMoDC |
ILT3+ILT4+ |
|
|
Chang et al., 2002 (329) |
|
| CD8+CD28− suppressor |
CD4+CD45RO+CD25+ |
huMoDC |
ILT3+ILT4+ |
|
|
Manavalan et al., 2003 (330) |
|
| CD4+ Tregs |
CD4+* |
BMDC |
|
|
|
Martin et al., 2003 (231) |
